Fatal events during clinical trials: an evaluation of deaths during breast cancer studies-Reference-Cited by-同舟云学术

Fatal events during clinical trials: an evaluation of deaths during breast cancer studies

Published:2019-06-28 Issue:6 Volume:26 Page:826-834
ISSN:1340-6868
Container-title:Breast Cancer
language:en
Short-container-title:Breast Cancer

Author:

Furlanetto Jenny,von Minckwitz Gunter,Lederer Bianca,Möbus Volker,Schneeweiss Andreas,Huober Jens,Fasching Peter A.,Gerber Bernd,Bauerfeind Ingo,Nitz Ulrike,Lück Hans-Joachim,Hanusch Claus,Thomssen Christoph,Untch Michael,Nekljudova Valentina,Mehta Keyur,Loibl Sibylle

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12282-019-00990-3.pdf

Reference35 articles.

1. Shamoo AE. Adverse events reporting—the tip of an iceberg. Account Res. 2001;8(3):197–218.

2. Food and Drug Administration. https://www.gpo.gov/fdsys/granule/CFR-2011-title21-vol5/CFR-2011-title21-vol5-sec312-33 . Accessed 02 Oct 2018.

3. Mansi BA, Clark J, David FS, Gesell TM, Glasser S, Gonzalez J, et al. Ten recommendations for closing the credibility gap in reporting industry-sponsored clinical research: a joint journal and pharmaceutical industry perspective. Mayo Clin Proc. 2012;87(5):424–9.

4. Penninckx B, Van de Voorde WM, Casado A, Reed N, Moulin C, Karrasch M. A systemic review of toxic death in clinical oncology trials: an Achilles’ heel in safety reporting revisited. Br J Cancer. 2012;107(1):1–6.

5. von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, et al. Neoadjuvant vinorelbine–capecitabine versus docetaxel–doxorubicin–cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008;100(8):542–51.